Substance P containing nerve fibers in ulcerative colitis

International Journal of Colorectal Disease

Volumn 13, Issue 2, 1998, Pages 61-67

  Watanabe, T ^a,b   Kubota, Y ^a   Muto, T ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE   (Japan)

Author keywords

Human colon; Inflammatory bowel disease; Neuropeptide; Substance P; Ulcerative colitis

Indexed keywords

SUBSTANCE P;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COLON MUCOSA; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; NERVE FIBER; PATHOGENESIS; PRIORITY JOURNAL; SCHOOL CHILD; ULCERATIVE COLITIS;

EID: 0031841110     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003840050136     Document Type: Article

References (44)

1. Debas HT, Mulvihill SJ (1991) Neuroendocrine design of the gut. Am J Surg 161:243-249
2. Shanahan F, Anton P (1988) Neuroendocrine modulation of the immune system. Dig Dis Sci 33:41-49
3. Polak JM, Bloom SR (1979) The neuroendocrine design of the gut. J Clin Endocrinol Metab 8:313-330
4. O'Doriso MS (1986) Neuropeptides and gastrointestinal immunity Am J Med 81:74-82
5. Mantyh CR, Vigna SR, Bollinger RR, Mantyh PW, Maggio JE, Pappas TN (1995) Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 109:850-860
6. Keranen U, Kiviluoto T, Jarvinen H, Back N, Kivilaakso E, Soinila S (1995) Changes in substance P immunoreactive innervation of human colon associated with ulcerative colitis. Dig Dis Sci 40:2250-2258
7. Goetzl EJ, Chernov T, Renold F, Payan DG (1985) Neuropeptide regulation of the expression of immediate hypersensitivity. J Immunol 135:802-805
8. O'Doriso MS, Wood CL, O'Doriso TM (1985) Vasoactive intestinal peptide and neuropeptide modulation of the immune response. J Immunol 135:792-796
9. Costa M, Patel Y, Furness JB, Arimura A (1977) Evidence that some intrinsic neurons of the intestine contain somatostatin. Neurosci Lett 6:215-222
10. Mayer EA, Raybould H, Koelbel C (1988) Neuropeptides, inflammation, and motility. Dig Dis Sci 33 [Suppl]:71S-77S
11. Miller RJ (1984) New Perspectives on gut peptides. J Med Chem 27:1239-1245
12. Payan DG, Hess CA, Goetzl EJ (1984) Inhibition by somatostatin of the proliferation of T-lymphocytes and Molt-4 lymphoblasts. Cell Immunol 84:433-438
13. MacDermott RP, Stenson WF (1988) Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 42:285-328
14. Kubota Y, Ottaway CA, Petras RE, Tubbs RR, Farmer RE, Fiocchi C (1989) Loss of vasoactive intestinal polypeptide (VIP) immunoreactive nerve fibers in the colon of inflammatory bowel disease patients. In: Macdonald TT, Challacombe SJ, Blanca PW, Stokes CR, Hestly RV, Mowat AM (eds) Kluwer, London, pp 717-718
15. Sjolund K, Schaffalitzky de Muckadell OB, Fahrenkrug J, Hakanson R, Peterson BG, Sundler F (1983) Peptide-containing nerve fibers in the gut wall in Crohn's disease. Gut 24:724-733
16. Bishop AE, Polak JM, Bryan MG, Bloom SR, Hamilton S (1980) Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease Gastroenterology 79:853-860
17. Koch TR, Carney JA, Morris VA, Vay Liang WG (1988) Somatostatin in the idiopathic inflammatory bowel diseases. Dis Col Rect 31:198-203
18. Koch TR, Carney JA, Vay Liang WG (1987) Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig Dis Sci 32:369-376
19. Dawson J, Bryant MG, Bloom SR, Peters TJ (1984) Gastrointestinal regulatory peptide storage granule abnormalities in jejunal mucosal diseases. Gut 25:636-643
20. Metwai A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV (1994) Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 52:69-78
21. McCafferty DM, Sharkey KA, Wallace JL (1994) Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol 266:G560-567
22. Reubi JC, Mazzucchelli L, Laissue JA (1994) Intestinal vessels express a high density of somatostatin receptors in human inflammatory bowel disease. Gastroenterology 106:951-959
23. Surrenti C, Renzi D, Garcea MR, Surrenti E, Salvadori G (1993) Colonic vasoactive intestinal polypeptide in ulcerative colitis. J Physiol (Paris) 87:307-311
24. Bemmstein CN, Robert ME, Eysselein VE (1993) Rectal substance P concentrations are increased in ulcerative colitis but not in Crohn's disease. Am J Gastroenterol 88:908-913
25. Kubota Y, Petras RE, Ottaway CA, Tubbs RR, Farmer RG, Fiocchi C (1992) Colonic vasoactive intestinal peptide nerves in inflammatory bowel disease. Gastroenterology 102:1242-1251
26. Kubota Y, Petras RE, Tubbs RR, Farmer RG, Fiocchi C, Ottaway CA (1991) Loss of vasoactive intestinal polypeptide immunoreactive nerve fibers in the colon of inflammatory bowel disease patients. In: Tsuchiya M, Nagura H, Hibi T, Moro I (eds) Frontiers of mucosal immunology. Excerptica Media, Amsterdam, pp 843-846
27. Mantyh PW, Catton MD, Boehmer CG, Welton ML, Passaro EP JR, Maggio JE, Vigna SR (1989) Receptors for sensory neuropeptides in human inflammatory diseases: implications for the effector role of sensory neurons. Peptides 10:627-645
28. Hagermark O, Hokfelt T, Pernow B (1978) Flare and itch induced by substance p in human skin. J Invest Dermatol 71:233-235
29. Lembeck F, Holzer P (1979) Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 310:175-183
30. Mandahl A, Bill A (1981) Ocular responses to antidromic trigeminal stimulation, intracameral prostaglandin E1 and E2, capsaicin and substance P. Acta Physiol Scand 112:331-338
31. McCafferty DM, Sharkey KA, Wallace JL (1994) Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol 266:G560-G567
32. Levine JD, Moskowitz MA, Basbaum AI (1985) The contribution of neurogenic inflammation in experimental arthritis. J Immunol 135:843-846
33. Lotz M, Carson DA, Vaughan JH (1987) Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 235:893-895
34. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI (1984) Intraneuronal substance P contributes to the severity of experimental arthritis. Science 226:547-549
35. Payan DG, Brewster DR, Goetzl EJ (1983) Specific stimulation of human T lymphocytes by substance P. J Immunol 131:1613-1615
36. Stanisz AM, Befus D Bienenstock J (1986) Differential effects of vasoactive intestinal polypeptide, substance P, and somatostatin on immunoglobulin synthesis and proliferations by lymphoocytes from Peyer's patches, mesenteric lymph nodes, and spleen. J Immunol 136:152-156
37. Riemann JF, Schmidt H (1982) Ultrastructural changes in the gut autonomic nervous system following laxative abuse and other conditions. Scand J Gastroenterol 17 [Suppl 71]:111-124
38. O'Morain C, Bishop AE, McGregor GP, Levi AJ, Bloom SR, Polak JM, Peters T (1984) Vasoactive intestinal peptide concentrations and immunohistochemical studies in rectal biopsies from patients with inflammatory bowel disease. Gut 25:57-61
39. Watanabe T, Kubota Y, Sawada T, Muto T (1992) Distribution and quantification of somatostatin in Inflammatory diseases. Dis Colon Rectum 35:488-494
40. Shanahan F, Denburg JA, Fox J Bienenstock J, Befus K (1985) Mast cell heterogeneity: Effect of neuroenteric peptides on histamine release. J Immunol 135:1331-1337
41. Foreman JC, Piotrowski W (1984) Peptides and histamine release. J Allergy Clin Immunol 74:127-131
42. Goetzl EJ, Payan DG (1984) Inhibition by somatostatin of the release of mediators from human basophils and rat leukemic basophils. J Immunol 133:3255-3259
43. Agerskov K, Bousfield R, Mortensen PE, Olsen J, Christiansen J (1986) Effect of somatostatin on 133Xe clearance from colonic mucosa before and after local nervous blickade in unanaesthetzed man. Scand J Gastroenterol 21:951-954
44. Adeyemi EO, Savage AP, Bloom SR, Hodgson HJF (1990) Somatostatin inhibits neutrophil elastase release in virto. Peptides 11:869-871